Hemoadsorption: consensus report of the 30th Acute Disease Quality Initiative workgroup

医学 重症监护医学 体外 临床试验 工作组 外科 内科学 计算机网络 计算机科学
作者
Rinaldo Bellomo,Ghada Ankawi,Sean M. Bagshaw,Ian Baldwin,Rajit K. Basu,Gabriella Bottari,Vincenzo Cantaluppi,William R. Clark,Silvia De Rosa,Lui G. Forni,Dana Y. Fuhrman,Stuart L. Goldstein,Hernando Gómez,Faeq Husain‐Syed,Michael Joannidis,Kianoush Kashani,Anna Lorenzin,Ravindra L. Mehta,Patrick Murray,Ragi Murugan
出处
期刊:Nephrology Dialysis Transplantation [Oxford University Press]
卷期号:39 (12): 1945-1964 被引量:17
标识
DOI:10.1093/ndt/gfae089
摘要

ABSTRACT Adsorption-based extracorporeal therapies have been subject to technical developments and clinical application for close to five decades. More recently, new technological developments in membrane and sorbent manipulation have made it possible to deliver more biocompatible extracorporeal adsorption therapies to patients with a variety of conditions. There are several key rationales based on physicochemical principles and clinical considerations that justify the application and investigation of such therapies as evidenced by multiple ex vivo, experimental and clinical observations. Accordingly, unspecific adsorptive extracorporeal therapies have now been applied to the treatment of a wide array of conditions from poisoning to drug overdoses, to inflammatory states and sepsis, and acute or chronic liver and kidney failure. In response to the rapidly expanding knowledge base and increased clinical evidence, we convened an Acute Disease Quality Initiative consensus conference dedicated to such treatment. The data show that hemoadsorption has clinically acceptable short-term biocompatibility and safety, technical feasibility and experimental demonstration of specified target molecule removal. Pilot studies demonstrate potentially beneficial effects on physiology and larger studies of endotoxin-based hemoadsorption have identified possible target phenotypes for larger randomized controlled trials. Moreover, in a variety of endogenous and exogenous intoxications, removal of target molecules has been confirmed in vivo. However, some studies have raised concerns about harm, or failed to deliver benefits. Thus, despite many achievements, modern hemoadsorption remains a novel and experimental intervention with limited data, and a large research agenda.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
yangling0124完成签到,获得积分10
1秒前
1秒前
1秒前
1秒前
2秒前
xxl完成签到,获得积分10
3秒前
3秒前
赘婿应助柚子苏采纳,获得10
3秒前
3秒前
Miranda完成签到,获得积分10
4秒前
renzhiqiang完成签到,获得积分10
4秒前
XHW完成签到,获得积分10
4秒前
英俊的铭应助syx采纳,获得10
5秒前
5秒前
里清水完成签到 ,获得积分10
6秒前
6秒前
流体离子发电机完成签到,获得积分10
6秒前
6秒前
6秒前
科研通AI5应助科研通管家采纳,获得10
7秒前
淡淡秋应助科研通管家采纳,获得10
7秒前
星绘发布了新的文献求助30
7秒前
大个应助feixue采纳,获得10
8秒前
乂领域应助科研通管家采纳,获得20
8秒前
天天快乐应助科研通管家采纳,获得10
8秒前
科研通AI5应助科研通管家采纳,获得10
8秒前
科研通AI6应助科研通管家采纳,获得10
8秒前
英俊的铭应助科研通管家采纳,获得10
8秒前
8秒前
传奇3应助科研通管家采纳,获得10
8秒前
Hello应助科研通管家采纳,获得10
8秒前
Lucas应助科研通管家采纳,获得10
8秒前
852应助slj采纳,获得10
8秒前
执着谷兰应助科研通管家采纳,获得10
8秒前
wanci应助科研通管家采纳,获得10
8秒前
科研通AI6应助科研通管家采纳,获得10
8秒前
情怀应助科研通管家采纳,获得10
8秒前
8秒前
Nico多多看paper完成签到,获得积分10
8秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各位详细阅读】【科研通的精品贴汇总】 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
F-35B V2.0 How to build Kitty Hawk's F-35B Version 2.0 Model 2000
줄기세포 생물학 1000
The Netter Collection of Medical Illustrations: Digestive System, Volume 9, Part III - Liver, Biliary Tract, and Pancreas (3rd Edition) 600
Founding Fathers The Shaping of America 500
中国减肥产品行业市场发展现状及前景趋势与投资分析研究报告(2025-2030版) 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 物理化学 基因 催化作用 遗传学 冶金 电极 光电子学
热门帖子
关注 科研通微信公众号,转发送积分 4520227
求助须知:如何正确求助?哪些是违规求助? 3962622
关于积分的说明 12281576
捐赠科研通 3625868
什么是DOI,文献DOI怎么找? 1995491
邀请新用户注册赠送积分活动 1031556
科研通“疑难数据库(出版商)”最低求助积分说明 922097